Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. For two decades, U.S.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care.

Therapy 91

Therapy Legalization Chronic Pain DEA 91

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Veriheal

JUNE 30, 2023

Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. Not all alternative medicine advocates are in support of the Natural Medicine Health Act, however.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

SpeedWeed

MAY 15, 2021

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The subjects were randomly divided into two groups, each of which received three individual sessions of talk therapy. Image via.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law 105

Law Research and Development Therapy DEA 105

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. Drug Enforcement Agency (DEA). This means that U.S. Is the future exciting? .”

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

FEBRUARY 28, 2022

Moreover, because Indigenous communities pioneered many aspects of modern psychedelic therapies, their patenting by Western corporations may promote biopiracy, the exploitation of Indigenous knowledge without compensation. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study , 27 NATURE MED.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

NewsMunchies

NOVEMBER 12, 2021

State-level ballot measures may further broaden the legal circumstances and settings in which psychedelics can be used for mental health therapy. The problem is, under federal law, psilocybin remains a prohibited Schedule 1 Drug, defined by the DEA as having “no currently accepted medical use and a high potential for abuse.”

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare. “Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. NEWS PROVIDED BY. ” Mr. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” 5520), and the Veterans Equal Access Act (H.R. However, it is clear that there is momentum to give veterans access to cannabis.

Law 62

Law Chronic Pain Conditions Legislation 62

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The Next Move Is On The DEA.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Veriheal

DECEMBER 27, 2022

Scientists Hope New Findings Will Help Expand Research on Psychedelic Therapy. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

Research and Development 95

Research and Development Therapy Consumption DEA 95

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. Breakthrough Therapy status obtained by COMPASS Pathways and Usona Institute. Breakthrough Therapy.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

SpeedWeed

JULY 22, 2021

The attorney general can also choose to waive that right and let the DEA review the petition instead. . Each day cannabis remains overly scheduled, patients and researchers across the United States continue to lose access to life-saving therapies and data.”. And Joyce and Young’s cannabis activism doesn’t end there.

DEA 52

DEA Therapy Cannabis Patients 52

Cannabis Law Report

AUGUST 12, 2022

Obtaining DEA License to Grow Psilocybin Mushrooms. For this event , panelists such as MAPS researcher Dorna Pourang and attorney Matt Zorn would talk about “the state of psychedelic therapy, the challenges and opportunities ahead, and how the medical system will make room for psychedelics.”. Psychedelics in the Healthcare System.

Research and Development 52

Research and Development Events Topical Policy 52

Cannabis Law Report

JULY 30, 2019

Like others, Dr. Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Cannabis is not a “gateway” drug, according to the ASA and the DEA’s own statements cited in the August 2016 U.S.

Marijuana 45

Marijuana Patients Research and Development Programs 45

The Cannigma

FEBRUARY 16, 2022

So, with that, we should get into it, but don’t forget to check out our segment with Americans for Safe Access. We always have a nice little tidbit when we’re all about advocacy and access to cannabis for all. It’s Dr. Codi Peterson here with our regularly scheduled segment with Americans for Safe Access.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73